BioCentury
ARTICLE | Company News

Aslan gains rights to preclinical asthma product from CSL

May 14, 2014 1:30 AM UTC

Aslan Pharmaceuticals Pte. Ltd. (Singapore) gained worldwide rights to CSL334 from CSL Ltd. (ASX:CSL). The human mAb against IL-13 receptor alpha 1 (IL-13RA1; IL-13Ra; CD213A1) is in preclinical testing to treat asthma. Aslan will fund and develop CSL334 through clinical proof of concept, after which the company will seek a worldwide partner for Phase III development and commercialization. Aslan will conduct trials primarily in Asia in patients with allergic asthma whose disease is not adequately controlled by existing treatments.

CSL will be eligible to share returns generated by Aslan from partnering the project but the partners could not be reached for details. ...